| Property | Value | [1]
|----------|-------| [2]
| Gene Symbol | SORCS1 |
| Full Name | Sortilin-Related VPS10 Domain Containing Receptor 1 |
| Chromosomal Location | 10q25.3 |
| NCBI Gene ID | 22998 |
| OMIM ID | 606283 |
| Ensembl ID | ENSG00000146433 |
| UniProt ID | Q9Y6J0 |
| Encoded Protein | Sortilin-related receptor 1 |
| Associated Diseases | Alzheimer's Disease (risk factor), Type 2 Diabetes (association), Late-Onset Parkinson's Disease |
SORCS1 is a human gene whose product sORCS1** encodes a member of the sortilin family of VPS10P domain receptors. SORCS1 is a transmembrane receptor expressed primarily in the brain that participates in intracellular protein trafficking and signaling. Variants in SORCS1 have been implicated in Alzheimer's Disease, Type 2 Diabetes, Parkinson's Disease. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
SORCS1 encodes a member of the sortilin family of VPS10P domain receptors. SORCS1 is a transmembrane receptor expressed primarily in the brain that participates in intracellular protein trafficking and signaling.
Key normal physiological functions include:
SORCS1 is a confirmed risk gene for late-onset AD:
Pathogenic mechanisms:
SORCS1 shows brain-enriched expression:
Subcellular localization: Endoplasmic reticulum, Golgi apparatus, endosomes
SORCS1-null mice exhibit significant phenotypes:
Neuronal SORCS1 overexpression:
Different genetic backgrounds show variable phenotypes, indicating modifier genes influence SORCS1 function.
Clinical genetic testing for SORCS1 variants available:
Considerations for patients and families:
SORCS1 contains multiple functional domains:
SORCS1 generates multiple splice variants with tissue-specific expression patterns.
SORCS1 plays a critical role in regulating amyloid precursor protein (APP) processing and trafficking through multiple mechanisms:
SORCS1 deficiency contributes to synaptic deficits in AD:
Drug development efforts targeting SORCS1:
| Agent | Mechanism | Development Stage |
|---|---|---|
| SORCS1 agonists | Upregulate expression | Preclinical |
| VPS10P domain blockers | Block Aβ binding | Research |
| Trafficking modulators | Normalize APP processing | Investigational |
AAV-mediated SORCS1 delivery to restore function.
SORCS1 interacts with:
| Partner | Interaction Type | Functional Consequence |
|---|---|---|
| APP | Direct binding | Affects Aβ production |
| BACE1 | Substrate competition | Modulates proteolysis |
| BDNF | Receptor binding | Neurotrophin signaling |
| NGF | Receptor binding | Neuronal survival |
| SorLA | Co-trafficking | Endosomal sorting |
SORCS1-/- mice show:
SORCS1 overexpression protects against Aβ toxicity.
Multiple GWAS have replicated SORCS1 as an AD risk locus:
SORCS1 levels in CSF correlate with cognitive decline.
Current research priorities:
Lane et al. SORCS1 and APP trafficking (2010). 2010. ↩︎
Goodyer et al. SORCS1 and diabetes (2008). 2008. ↩︎